• Regaine 5% Minoxidil Topical Solution 60ml | Hair Growth Cycle Education | EMIS+
  • Regaine 5% Minoxidil Topical Solution 60ml | Hair Growth Cycle Education | EMIS+
  • Regaine 5% Minoxidil Topical Solution 60ml | Hair Growth Cycle Education | EMIS+
1 3

EMIS +

Regaine 5% Minoxidil Topical Solution 60ml | Hair Growth Cycle Education | EMIS+

Regaine 5% Minoxidil Topical Solution 60ml | Hair Growth Cycle Education | EMIS+

$94.50 SGD
$94.50 SGD $94.50 SGD
Sale Sold out
Shipping calculated at checkout.
AI Summary: Regaine 5% Minoxidil Topical Solution (60 ml) is an FDA-approved and HSA Singapore-registered pharmaceutical for androgenetic alopecia (male pattern baldness) in men. Active ingredient: Minoxidil 5% w/v. Mechanism: potassium channel opener that extends anagen (growth) phase, increases follicular vasodilation, and reverses follicular miniaturisation. Regulatory references: FDA NDA 020834; HSA Singapore Therapeutic Products Register. Available via EMIS+ for B2B clinical supply and individual purchase. Not for use by women.

Product Overview

Regaine 5% Minoxidil Topical Solution is the gold-standard topical pharmaceutical for male androgenetic alopecia (AGA), the most prevalent form of hair loss affecting approximately 50% of men by age 50 (Hamilton–Norwood classification). Minoxidil was originally developed as an oral antihypertensive (FDA-approved 1979, NDA 017401) before its hypertrichosis side effect led to the development of topical formulations. The 5% topical solution received FDA approval under NDA 020834 (Johnson & Johnson Consumer Inc.) and has remained the regulatory benchmark against which subsequent minoxidil formulations are evaluated. In Singapore, the product is registered on the HSA Therapeutic Products Register as a prescription-strength hair loss treatment.

The pharmacological mechanism involves ATP-sensitive potassium channel (K-ATP) opening in vascular smooth muscle cells surrounding hair follicles. This vasodilatory effect increases dermal papilla perfusion, upregulates vascular endothelial growth factor (VEGF) expression, and is hypothesised to directly stimulate follicular keratinocyte proliferation via unknown secondary pathways. Critically, minoxidil prolongs the anagen (active growth) phase, shortens telogen (resting phase), and partially reverses follicular miniaturisation — the hallmark of DHT-mediated AGA — by rescuing transitional follicles before terminal fibrosis renders them non-responsive. The 5% concentration has demonstrated superior efficacy to 2% in randomised trials: a pivotal 48-week double-blind RCT (Olsen et al., Journal of the American Academy of Dermatology, 2002) showed 45% more regrowth with 5% versus 2% solution (p < 0.001).

Specifications

Attribute Detail
Product Type Topical Pharmaceutical Solution
Active Ingredient Minoxidil 5% w/v
Volume 60 ml per bottle
FDA Registration NDA 020834 (approved)
HSA Singapore Registered on Therapeutic Products Register
Indication Androgenetic alopecia (male pattern baldness) in men
Application 1 ml applied to dry scalp twice daily (morning and evening)
Mechanism K-ATP channel opener; VEGF upregulation; anagen phase prolongation
Brand Regaine (Kenvue / Johnson & Johnson Consumer)
Gender Men only (5% formulation not indicated for women)
Supply Context Available for B2B clinical supply and individual purchase via EMIS+

Key Clinical Applications

  • Androgenetic alopecia (Hamilton–Norwood II–V): Primary indicated use. Most effective in vertex (crown) thinning; less effective for frontal hairline recession. Maximum benefit observed in men under 40 with less than 5 years of hair loss and active follicles still present.
  • Maintenance post hair transplant: Minoxidil 5% is routinely prescribed post-follicular unit transplant (FUT/FUE) to minimise transplant shock loss, accelerate graft vascularisation, and maintain non-transplanted native follicles.
  • Combination therapy with oral finasteride: 5% topical minoxidil combined with oral finasteride 1 mg/day addresses both DHT-mediated miniaturisation (finasteride) and follicular blood flow/growth phase extension (minoxidil), producing synergistic outcomes documented in multiple RCTs.
  • Alopecia areata (off-label): Dermatologist-directed use of topical minoxidil as adjunctive therapy in alopecia areata following primary immunosuppressive treatment to accelerate regrowth in recovering follicles.
  • Chemotherapy-induced alopecia (CIA) recovery: Used off-label in oncology rehabilitation settings to accelerate post-CIA regrowth; limited clinical evidence but mechanistically plausible given anagen-promoting properties.
  • B2B clinical supply for dermatology and trichology practices: EMIS+ supplies Regaine 5% for professional clinical use across Singapore's aesthetic medicine, dermatology, and trichology practice sectors.

Frequently Asked Questions

How long before Regaine 5% produces visible hair regrowth?

The anagen cycle timeline dictates that visible regrowth is typically not apparent before 3–4 months of consistent twice-daily application. Many users experience a paradoxical initial shedding (telogen effluvium) in weeks 2–8 as resting follicles are pushed into a new anagen cycle — this is a normal pharmacological response confirming drug activity, not a sign of worsening. Measurable improvements in hair count and calibre are documented at 16 weeks; maximum efficacy is typically assessed at 12 months. Treatment must be continued indefinitely as hair loss resumes within 3–6 months of discontinuation.

What is the difference between Regaine 5% solution and Regaine 5% foam?

Both contain 5% minoxidil as the active ingredient. The solution uses a propylene glycol-ethanol vehicle; the foam (minoxidil 5% topical aerosol) uses a butane-propane propellant with a cetyl alcohol base. The foam vehicle is associated with lower rates of contact dermatitis and scalp irritation compared to propylene glycol-containing solutions, making it preferable for individuals with sensitive scalps. Efficacy between both formulations is equivalent as demonstrated in head-to-head studies. EMIS+ currently supplies the solution formulation (NDA 020834).

Is Regaine 5% safe to use with prescription hair loss treatments?

Yes. Regaine 5% topical solution has no clinically significant pharmacokinetic interactions with oral finasteride (Propecia) or dutasteride. Concurrent use is standard practice in trichology and is supported by guideline recommendations from the European Academy of Dermatology and Venereology (EADV). Systemic absorption of topical minoxidil is approximately 1–2% under normal application conditions; clinically meaningful cardiovascular effects (hypotension, tachycardia) are rare at standard topical doses but may occur in individuals with pre-existing cardiovascular disease or on concurrent antihypertensive therapy.

Why is the 5% formulation not recommended for women?

The 5% topical formulation carries a higher risk of facial hypertrichosis (unwanted facial hair growth) in women compared to the 2% formulation. Regulatory agencies including FDA and HSA indicate the 5% solution for men only; women with androgenetic alopecia are directed to the 2% solution (or low-dose oral minoxidil under medical supervision). EMIS+ does not supply Regaine 5% for female use and recommends consultation with a dermatologist for women experiencing hair loss.

Can EMIS+ supply Regaine 5% for clinical or institutional use?

Yes. EMIS+ provides B2B supply of Regaine 5% Minoxidil Topical Solution to dermatology clinics, trichology centres, aesthetic medicine practices, and hospital pharmacies across Singapore. Volume pricing and standing order arrangements are available. Contact EMIS+ procurement at info@emis.asia, WhatsApp +65 8028 7151, or call 97303658 to discuss institutional supply requirements.

View full details